Reports of potential U.S. tariffs on imported pharmaceuticals — with rates discussed at levels that would be unprecedented for the sector — have prompted serious planning discussions across API manufacturing operations in Asia. While the policy details remain fluid, any broad tariff measure would reshape the economics of API production and export in ways that manufacturers need to prepare for now, not after implementation.
Why it matters for API manufacturers
• Production cost calculations must factor in potential tariff exposure when quoting for U.S.-destined orders. Manufacturers who can demonstrate value-added processing steps — such as advanced purification, polymorph screening, or particle engineering — may be better positioned to justify pricing adjustments to buyers.
• Demand patterns could shift as U.S. formulators accelerate purchases ahead of tariff deadlines or redirect sourcing to facilities in tariff-neutral jurisdictions. Manufacturers with production sites in multiple countries, or those able to offer flexible Incoterms and bonded warehouse arrangements, will have a structural advantage.
• For Chinese API manufacturers specifically, this reinforces the strategic importance of diversifying export markets. Companies that have invested in EU CEP filings, WHO prequalification, or registrations in Latin American and ASEAN markets will be less exposed to any single-country trade policy shift.
At our facilities, we are reviewing our cost structures and logistics options to ensure we can support customers regardless of how the tariff situation develops. This includes evaluating partnerships with toll manufacturers in regions that may offer tariff advantages and strengthening our documentation packages to support any re-registration or import classification needs.